Survival time and prognostic factors in dogs clinically diagnosed with haemangiosarcoma in UK first opinion practice

Visceral haemangiosarcoma is considered clinically aggressive in dogs, with perceived poor prognosis often leading to euthanasia at presentation. This study aimed to determine survival times and prognostic factors in dogs with haemangiosarcoma under first-opinion care. Dogs clinically diagnosed with haemangiosarcoma in first-opinion practice in 2019 were identified in VetCompass electronic health records and examined to capture variables potentially associated with survival. Median survival time (MST) from diagnosis was calculated for the whole population, those histopathologically confirmed and based on primary tumour location. Binary logistic regression was used to explore differences between dogs that died on the day of diagnosis and those that survived ≥1 day. Cox proportional hazards modelling explored factors associated with time to death in dogs surviving ≥1 day. Across all cases (n = 788), overall MST was 9.0 days (95%CI:5.0-15.0, range: 0-1789) and proportional 1-year survival was 12.0% (95%CI:9.7-15.0%). Dogs with splenic (MST = 4.0 days, 95%CI 0.0-9.0) and cutaneous haemangiosarcoma (MST = 119.0 days,95%CI:85.0-248.0) had MST greater than 0 days. Of dogs with a histopathological diagnosis of haemangiosarcoma, overall MST was longer at 105 days (95% CI 84-133 days) and additionally, location-specific MST were longer. For both clinically diagnosed cases and histopathologically confirmed cases, increasing tumour size was associated with increased hazard of death while cutaneous location and surgery were associated with reduced hazard of death. A very short survival time was identified for haemangiosarcoma under first-opinion care. Although survival time was longest for cutaneous cases, the actualised prognosis was poor overall for haemangiosarcoma. However, a common prevailing view of extremely poor prognosis for haemangiosarcoma could be promoting frequent euthanasia at presentation and therefore leading to a self-fulfilling prophecy and low survival times. Further exploration of the potential effect of perceived prognosis is warranted. This study provides valuable information for contextualised care and dialogues with clients in first-opinion practice.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2025-06-06
DOI
https://doi.org/10.1371/journal.pone.0316066
Citations
6
Primary Topic
Veterinary Oncology Research
Type
article
Field-Weighted Citation Impact
9.11

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Survival time and prognostic factors in dogs clinically diagnosed with haemangiosarcoma in UK first opinion practice

Dan Gerard O'Neill, Julia Labadie, Dave C. Brodbelt, Alexandra Guillén et al.
6 citations
PLoS ONE
Veterinary Oncology Research
9.11
article

Survival time and prognostic factors in dogs clinically diagnosed with haemangiosarcoma in UK first opinion practice

Dan Gerard O'Neill, Julia Labadie, Dave C. Brodbelt, Alexandra Guillén, Collette Taylor, Phoebe Pickard Price, Georgina Barry
article en
6 citations

Abstract

Visceral haemangiosarcoma is considered clinically aggressive in dogs, with perceived poor prognosis often leading to euthanasia at presentation. This study aimed to determine survival times and prognostic factors in dogs with haemangiosarcoma under first-opinion care. Dogs clinically diagnosed with haemangiosarcoma in first-opinion practice in 2019 were identified in VetCompass electronic health records and examined to capture variables potentially associated with survival. Median survival time (MST) from diagnosis was calculated for the whole population, those histopathologically confirmed and based on primary tumour location. Binary logistic regression was used to explore differences between dogs that died on the day of diagnosis and those that survived ≥1 day. Cox proportional hazards modelling explored factors associated with time to death in dogs surviving ≥1 day. Across all cases (n = 788), overall MST was 9.0 days (95%CI:5.0-15.0, range: 0-1789) and proportional 1-year survival was 12.0% (95%CI:9.7-15.0%). Dogs with splenic (MST = 4.0 days, 95%CI 0.0-9.0) and cutaneous haemangiosarcoma (MST = 119.0 days,95%CI:85.0-248.0) had MST greater than 0 days. Of dogs with a histopathological diagnosis of haemangiosarcoma, overall MST was longer at 105 days (95% CI 84-133 days) and additionally, location-specific MST were longer. For both clinically diagnosed cases and histopathologically confirmed cases, increasing tumour size was associated with increased hazard of death while cutaneous location and surgery were associated with reduced hazard of death. A very short survival time was identified for haemangiosarcoma under first-opinion care. Although survival time was longest for cutaneous cases, the actualised prognosis was poor overall for haemangiosarcoma. However, a common prevailing view of extremely poor prognosis for haemangiosarcoma could be promoting frequent euthanasia at presentation and therefore leading to a self-fulfilling prophecy and low survival times. Further exploration of the potential effect of perceived prognosis is warranted. This study provides valuable information for contextualised care and dialogues with clients in first-opinion practice.

PLoS ONEVol. 20(6)
Royal Veterinary College (GB), Morris Animal Foundation (US)
Morris Animal Foundation
Good health and well-being
Openalex Percentile: Top 2%
Veterinary Oncology Research
9.11
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.